Company Description
FOXO Technologies Inc. develops epigenetic biomarkers technology solutions in the United States.
The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging.
It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers.
FOXO Technologies Inc. was founded in 2020 and is based in Minneapolis, Minnesota.
| Country | United States |
| Founded | 2019 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Mark White |
Contact Details
Address: 729 North Washington Avenue, Suite 600 Minneapolis, Minnesota 55401 United States | |
| Phone | 612 562 9447 |
| Website | foxotechnologies.com |
Stock Details
| Ticker Symbol | FOXO |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001812360 |
| ISIN Number | US3514713052 |
| Employer ID | 85-1050265 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Mark Brian White | Interim Chief Executive Officer and Director |
| Martin Christopher Ward FCA | Interim Chief Financial Officer |
| Jim Grauel Jr. | Chief Distribution Officer |
| Susan Neo | Chief Security Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 10-Q | Quarterly Report |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 18, 2024 | DEFR14A | Filing |
| Nov 15, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 14, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 29, 2024 | D | Notice of Exempt Offering of Securities |
| Oct 28, 2024 | D | Notice of Exempt Offering of Securities |
| Oct 25, 2024 | 8-K | Current Report |
| Oct 24, 2024 | PRE 14A | Other preliminary proxy statements |